In yesterday’s Wall Street session, Immunic Inc. (NASDAQ:IMUX) shares traded at $2.57, down -10.45% from the previous session.
4 analysts cover Immunic Inc. (NASDAQ:IMUX), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $5.00, we find $10.00. Given the previous closing price of $2.87, this indicates a potential upside of 248.43 percent. IMUX stock price is now 45.90% away from the 50-day moving average and 18.68% away from the 200-day moving average. The market capitalization of the company currently stands at $96.20M.
The stock has received a hold rating from 1 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $13.25 as their price target over the next twelve months.
With the price target maintained at $5, SVB Leerink recently Downgraded its rating from Outperform to Mkt Perform for Immunic Inc. (NASDAQ: IMUX).
In other news, Whaley Glenn, Chief Financial Officer bought 5,000 shares of the company’s stock on May 15. The stock was bought for $8,750 at an average price of $1.75. Upon completion of the transaction, the Chief Financial Officer now directly owns 25,510 shares in the company, valued at $65560.7. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 14, Director Neermann Joerg bought 47,000 shares of the business’s stock. A total of $59,032 was incurred on buying the stock at an average price of $1.26. This leaves the insider owning 100,000 shares of the company worth $0.26 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IMUX stock. A new stake in Immunic Inc. shares was purchased by DEEP TRACK CAPITAL, LP during the first quarter worth $6,487,000. LOGOS GLOBAL MANAGEMENT LP invested $1,082,000 in shares of IMUX during the first quarter. In the first quarter, RENAISSANCE TECHNOLOGIES LLC acquired a new stake in Immunic Inc. valued at approximately $970,000. SOLEUS CAPITAL MANAGEMENT, L.P. acquired a new stake in IMUX for approximately $771,000. SCHONFELD STRATEGIC ADVISORS LLC purchased a new stake in IMUX valued at around $342,000 in the second quarter. In total, there are 86 active investors with 44.70% ownership of the company’s stock.
On Thursday morning Immunic Inc. (NASDAQ: IMUX) stock kicked off with the opening price of $2.8000. During the past 12 months, Immunic Inc. has had a low of $1.11 and a high of $11.76. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.50, and a quick ratio of 6.50. The fifty day moving average price for IMUX is $1.7825 and a two-hundred day moving average price translates $2.1587 for the stock.
The latest earnings results from Immunic Inc. (NASDAQ: IMUX) was released for Mar, 2023.
Immunic Inc.(IMUX) Company Profile
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
